Sarepta Therapeutics' stock has reached its lowest point in a year, even though the company reported strong earnings and positive clinical news, which highlights difficulties in the biotech sector and investor feelings. In the fourth quarter of 2024, the company experienced a 75% year-over-year revenue increase, largely due to Elevidys, with net income rising to $159.049 million and earnings per share of $1.50. Sarepta is developing gene therapies for conditions like LGMD, FSHD, and DM1, which have considerable market potential, although not as significant as DMD.
SRPT has shared mixed results for the fourth quarter of 2024. The company has finalized a multi-billion-dollar agreement with Arrowhead and introduced four new clinical programs to its development pipeline.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) will hold its Q4 2024 earnings conference call on February 26, 2025, at 4:30 PM ET. The call will feature key company participants, including Mary Jenkins, Doug Ingram, and Dr. Louise Rodino-Klapac, along with various analysts from major financial institutions. The operator will welcome everyone to the call, which will discuss the company's financial results for the fourth quarter and the entire year.
Sarepta Therapeutics (SRPT) reported quarterly earnings of $1.50 per share, which is lower than the Zacks Consensus Estimate of $1.87 per share. In comparison, the company earned $0.47 per share during the same period last year.
Sarepta Therapeutics (SRPT) has shown a hammer chart pattern, suggesting that the stock has found support after a recent decline. Additionally, the increase in earnings estimate revisions may indicate a potential trend reversal for the stock soon.
Sarepta Therapeutics (SRPT) may have reached a point where the intense selling has slowed down, as it is now considered oversold. Furthermore, the consensus among Wall Street analysts to raise earnings estimates suggests that the stock could be ready for a change in direction.
We just released an article called Jim Cramer’s Lightning Rounds: 9 Stocks in Focus. In this piece, we will examine how Sarepta Therapeutics, Inc. (NASDAQ:SRPT) compares to other stocks. Jim Cramer, the host of Mad Money, recently shared his worries about the unclear economic situation for 2025, especially in […]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leader in precision genetic medicine for rare diseases, has shared encouraging initial results from Part 2 of the EMBARK study (Study SRP-9001-301). This global, randomized, double-blind, placebo-controlled Phase 3 clinical trial focuses on ELEVIDYS (delandistrogene moxeparvovec-rokl), the only gene therapy approved for patients with Duchenne muscular dystrophy. Patients who were given a placebo in Part 1 and later received treatment showed positive outcomes.
Sarepta Therapeutics' Elevidys for DMD is expected to generate increasing revenue, with management aiming for over $3 billion in total revenues by 2025, a 68% rise from 2024, driven by the gene therapy. Although there have been worries about its valuation in the past, Sarepta's current market cap of $11.4 billion seems reasonable, with the possibility of more than a 50% increase by the end of 2025. While Elevidys has a high price and mixed clinical results, the overall evidence indicates it could be the best treatment option for DMD, with no immediate competitors.
A jury in Delaware announced on Friday that Japanese pharmaceutical company Nippon Shinyaku violated a Sarepta patent connected to its DMD drug, Vyondys 53, and is required to pay $115.2 million in damages.